Predicta Med
Connecting the Dots of Undiagnosed Diseases
Company Overview
Snapshot
Founded in January 2020 by Shlomit Steinberg-Koch and Benny Getz, Predicta Med operates with 11–50 employees. The company has raised $5.5 million across two funding rounds, with CerraCap Ventures as an investor. In January 2024, Predicta Med secured a grant from the Israel Innovation Authority.
Business overview
Predicta Med provides an AI-powered platform designed for the early detection and intervention selection of autoimmune diseases. Its core technology leverages deep learning to aggregate, enrich, and analyze EMR and claims data, aiming to shorten the diagnostic process for healthcare providers. The platform identifies patients at risk of autoimmune diseases and offers actionable insights to optimize intervention, serving the healthcare industry within the Digital Health and Medical Decision Support sectors.
Strategic signal
In July 2023, Predicta Med joined the Cedars-Sinai Accelerator, a significant validation of its technology and market potential. This signals strong institutional interest and provides the company with access to a leading medical institution, which can accelerate product development, clinical validation, and market penetration for its AI-powered diagnostic platform.
Company Intelligence Q&A
- What is Predicta Med's primary focus?
- Predicta Med focuses on enabling the early detection and intervention selection of autoimmune diseases through an AI-powered platform that analyzes EMR and claims data.
- When was Predicta Med founded?
- Predicta Med was founded in January 2020 by Shlomit Steinberg-Koch and Benny Getz.
- What was a key strategic development for Predicta Med in 2023?
- In July 2023, Predicta Med joined the Cedars-Sinai Accelerator, indicating a strategic partnership and validation within the health-tech ecosystem.
- Has Predicta Med received any grants?
- In January 2024, Predicta Med secured a grant from the Israel Innovation Authority.
- What is the total capital raised by Predicta Med?
- Predicta Med has raised a total of $5.5 million across two funding rounds.